Sign In
Search Icon
Menu Icon

SNS Products: Vaccines and Treatment Available for Use in the Mpox Response


monkeypox'

ASPR’s Strategic National Stockpile (SNS), in coordination with the Centers for Disease Control and Prevention, is deploying vaccines and treatments to a number of jurisdictions across the United States to support communities affected by mpox.


Vaccines

The SNS holds both JYNNEOS and ACAM2000 vaccines that could be used to protect people from mpox infections. ASPR’s Biomedical Advanced Research and Development Authority (BARDA) supported the development of JYNNEOS, which is approved by the U.S. Food and Drug Administration (FDA) to prevent both smallpox and mpox. ACAM2000®, which was developed with support from SNS, is FDA approved for smallpox but could also be used to vaccinate at-risk individuals under an appropriate regulatory mechanism outside its labeled indication. CDC currently has an expanded access Investigational New Drug protocol that allows its use for mpox.

JYNNEOS vaccine may be shipped either frozen or refrigerated and requires specific cold chain requirements for storage. The requirements for shipment and storage differ from the package insert. Before requesting product, read Bavarian Nordic’s letter on storage requirements for JYNNEOS vaccine and ensure you have a plan to meet these requirements.  

Following a Section 564 determination, the FDA announced an alternate strategy that allows health care providers to draw up to five doses of JYNNEOS vaccine from a single vial when administered intradermally.

Table 1: Lot Numbers and Expiration Dates for SNS-held JYNNEOS vaccine

NDC # Lot Number(s) Expiration

50632-001-01 (vial) 
50632-001-02 (20 vials/package)

FDP00002
FDP00003
FDP00004
FDP00005

Aug 31, 2023 

50632-001-01 (vial) 
50632-001-02 (20 vials/package)

FDP00009

May 31, 2024

50632-001-01 (vial) 
50632-001-02 (20 vials/package)

FDP00012

Aug 31, 2024

50632-001-01 (vial) 
50632-001-02 (20 vials/package)

FDP00013
FDP00014
FDP00015

Sept 30, 2024

50632-001-01 (vial) 
50632-001-02 (20 vials/package)

FDP00016
FDP00017
FDP00018
FDP00019
FDP00020

Oct 31, 2024

50632-001-01 (vial) 
50632-001-02 (20 vials/package)

FDP00115

Jul 31, 2025

50632-001-01 (vial)
50632-001-02 (20 vials/package)

FDP00074

Jul 31, 2025

50632-001-01 (vial) 
50632-001-02 (20 vials/package)

FDP00117
FDP00118

Jul 31, 2025

50632-001-01 (vial)
50632-001-02 (20 vials/package)

FDP00117
FDP00118

Jul 31, 2025

50632-001-01 (vial) 
50632-001-02 (20 vials/package)

FDP00119
FDP00120

Aug 31, 2025


Antiviral Drug

The SNS has a supply of the smallpox antiviral drug TPOXX® (tecovirimat), which was developed with BARDA support and can be used to treat individuals with mpox with an appropriate regulatory mechanism. CDC currently has an expanded access Investigational New Drug protocol that allows its use for mpox.

The smallpox antiviral drug TPOXX® supplied by the SNS does not have an expiration date printed on its label. To determine the expiration date for product received from the SNS, find the lot number on the product label, and refer to the table below to identify the corresponding expiration date.

Table 2: Lot Numbers and Expiration Dates for SNS-held oral TPOXX (tecovirimat) 


Lot Number(s) Expiration

24601039
24601040
24601041
24601042
24601043
24601044

March 2023

24601045
24601050

April 2023

24601046
24601047
24601048
24601049
24601054

May 2023

24601051
24601052
24601053

September 2023

24601055
24601056
24601057
24601058

November 2023

24601059
24601060
24601063
24601064

January 2024

24601061
24601062
24601065

May 2024

24601066
24601067
24601068
24601069

June 2024

24601073

March 2026

24601075
24601076
24601077
24601078
24601079
24601080

February 2027

24601081
24601082
24601092

March 2027

24601093
24601094
24601095

May 2027

24601096
24601097
24601098
24601099
24601100
24601102

April 2028

24601101
24601103
24601104
24601105

May 2028


Table 3: Lot Numbers and Expiration Dates for SNS-held intravenous TPOXX (tecovirimat)

Lot Number(s) Expiration

​246V2083

7-Jan-2023

246V2084

25-May​​-2023​​

246V2085

21-Aug-2023

246V2087

31-May-2023

246V2088

30-Apr-2023

246V2089

31-Oct-2023

246V2090

31-May-2023

246V2091

31-May-2023


As of October 26, 2022, the SNS holds Brincidofovir (also known as Tembexa or CMX001). Brincidofovir is an antiviral medication that was approved by the FDA [PDF – 21 pages] for the treatment of human smallpox disease in adult and pediatric patients, including neonates.

Clinicians with mpox patients necessitating brincidofovir treatment need to submit an e-IND request to FDA by email (DDI.EIND@fda.hhs.gov) or phone 301-796-3400 or 1-855-543-3784 during normal business hours (8 am-4:30 pm ET M-F). During after hours, call the FDA Emergency Coordinator at 1-866-300-4374 or 301-796-8240 or email CDER-EIND@fda.hhs.gov and call the call the CDER Emergency Coordinator at 301-796-9900.

Treatment Information for Healthcare Professionals | Mpox | Poxvirus | CDC.

Table 1: Lot Numbers and Expiration Dates for SNS-held Tembexa 100mg tablets

NDC # Lot Number(s) Expiration

79622-010-04 (4 tablets per package)

023815
023820
023825

Dec 31, 2024 

79622-010-04 (4 tablets per package)

024255

Aug 31, 2025


<

Table 2: Lot Numbers and Expiration Dates for SNS-held Tembexa 10mg/ml oral suspension, 65ml

NDC # Lot Number(s) Expiration
79622-012-65 (bottle)

0000111036
0000111037

Jan 31, 2024 

79622-012-65 (bottle)

0000111038

Feb 28, 2024